Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA.
The company announced positive trial news for its pan-virus vaccine.
The company's Q4 update made investors feel a little better after receiving disappointing news last week.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.